Equities research analysts at Jefferies Financial Group initiated coverage on shares of Liquidia Technologies (NASDAQ:LQDA) in a research note issued on Thursday, Marketbeat Ratings reports. The firm set a “buy” rating and a $27.00 price target on the stock. Jefferies Financial Group’s target price would suggest a potential upside of 41.51% from the company’s previous close.
Several other research firms have also issued reports on LQDA. Cowen set a $40.00 target price on shares of Liquidia Technologies and gave the stock a “buy” rating in a report on Wednesday, October 31st. Zacks Investment Research lowered shares of Liquidia Technologies from a “hold” rating to a “sell” rating in a report on Wednesday. Wedbush began coverage on shares of Liquidia Technologies in a report on Tuesday, September 4th. They set an “outperform” rating and a $26.00 price objective for the company. Finally, Needham & Company LLC set a $32.00 price objective on shares of Liquidia Technologies and gave the company a “buy” rating in a report on Wednesday, October 31st. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Liquidia Technologies currently has a consensus rating of “Buy” and an average target price of $31.75.
Shares of NASDAQ:LQDA traded up $0.85 on Thursday, reaching $19.08. The company’s stock had a trading volume of 24,759 shares, compared to its average volume of 52,688. The company has a debt-to-equity ratio of 0.40, a current ratio of 6.27 and a quick ratio of 6.27. Liquidia Technologies has a 52-week low of $10.52 and a 52-week high of $38.46.
A number of institutional investors and hedge funds have recently made changes to their positions in LQDA. FMR LLC bought a new stake in Liquidia Technologies during the 3rd quarter valued at about $6,729,000. BlackRock Inc. bought a new stake in Liquidia Technologies during the 3rd quarter valued at about $5,924,000. Finally, Dean Capital Investments Management LLC bought a new stake in Liquidia Technologies during the 3rd quarter valued at about $1,483,000. Institutional investors own 0.01% of the company’s stock.
Liquidia Technologies Company Profile
Liquidia Technologies, Inc is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies.
Recommended Story: What do investors mean by earnings per share?
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.